Wolverine Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-37,926
| Closed | -$6.97M | – | 2851 |
|
|
2021
Q2 | $6.97M | Buy |
37,926
+5,428
| +17% | +$932K | 0.07% | 228 |
|
|
2021
Q1 | $4.97M | Buy |
32,498
+12,499
| +62% | +$1.93M | 0.05% | 244 |
|
|
2020
Q4 | $3.12M | Buy |
19,999
+17,440
| +682% | +$2.24M | 0.03% | 340 |
|
|
2020
Q3 | $292K | Buy |
2,559
+2,542
| +14,953% | +$274K | ﹤0.01% | 879 |
|
|
2020
Q2 | $1K | Buy |
+17
| New | +$1.8K | ﹤0.01% | 1508 |
|
|
2017
Q3 | – | Sell |
-350
| Closed | -$42K | – | 1661 |
|
|
2017
Q2 | $42K | Buy |
+350
| New | +$40.7K | ﹤0.01% | 1135 |
|
|
2016
Q1 | – | Sell |
-1,800
| Closed | -$343K | – | 1956 |
|
|
2015
Q4 | $343K | Sell |
1,800
-800
| -31% | -$140K | 0.01% | 739 |
|
|
2015
Q3 | $406K | Sell |
2,600
-100
| -4% | -$18.2K | 0.01% | 723 |
|
|
2015
Q2 | $488K | Hold |
2,700
| – | – | 0.01% | 652 |
|
|
2015
Q1 | $467K | Buy |
+2,700
| New | +$489K | 0.01% | 635 |
|
|
2014
Q4 | – | Sell |
-8,600
| Closed | -$1.43M | – | 2839 |
|
|
2014
Q3 | $1.43M | Buy |
+8,600
| New | +$1.41M | 0.03% | 374 |
|
|
2014
Q1 | – | Sell |
-6,100
| Closed | -$810K | – | 3123 |
|
|
2013
Q4 | $810K | Sell |
6,100
-2,100
| -26% | -$252K | 0.02% | 601 |
|
|
2013
Q3 | $952K | Buy |
8,200
+3,600
| +78% | +$395K | 0.02% | 555 |
|
|
2013
Q2 | $424K | Buy |
+4,600
| New | +$443K | 0.01% | 806 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM